Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.30 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.30 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.30 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.30 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.30 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.30 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3303588 | 0.82 | KDM4E (0.41) | MAPK1ADRA2AADRA2BADRA2CADRA1D | |
| SCHEMBL16040498 | 0.78 | MAPK1 (0.33) | MAPK1ALDH1A1ALOX15MAPK10HSD17B10 | |
| SCHEMBL30217734 | 0.78 | MAPK1 (0.33) | MAPK1ALDH1A1ALOX15MAPK10HSD17B10 | |
| SCHEMBL3305107 | 0.77 | NQO2 (0.39) | MAPK1HSD17B10 | |
| SCHEMBL18388861 | 0.75 | HTT (0.36) | MAPK1ALDH1A1ALOX15MAPK10HSD17B10 | |
| SCHEMBL29639045 | 0.75 | HTT (0.36) | MAPK1ALDH1A1ALOX15MAPK10HSD17B10 | |
| SCHEMBL3312075 | 0.75 | THRB (0.37) | MAPK1ALDH1A1HSD17B10 | |
| SCHEMBL3304131 | 0.75 | ALDH1A1 (0.40) | ALDH1A1ALOX15MAPK10HSD17B10 | |
| SCHEMBL25222485 | 0.74 | ADRA2A (0.41) | MAPK1ALDH1A1ALOX15HSD17B10ADRA2A | |
| SCHEMBL30486566 | 0.74 | ADRA2A (0.41) | MAPK1ALDH1A1ALOX15HSD17B10ADRA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102197031-A | Substituted 5-aminopyrazoles and use thereof | BAYER SCHERING PHARMA AG | 2011-09-21 | — | — | CN | disclosed |
| US-20100099681-A1 | SUBSTITUTED 5-AMINOPYRAZOLES AND USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-04-22 | — | — | US | disclosed |
| US-20100099681-A1 | SUBSTITUTED 5-AMINOPYRAZOLES AND USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-04-22 | — | — | US | disclosed |
| US-20100099681-A1 | SUBSTITUTED 5-AMINOPYRAZOLES AND USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-04-22 | — | — | US | disclosed |
| WO-2010020363-A1 | SUBSTITUTED 5-AMINOPYRAZOLES AND USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-02-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100099681-A1 | SUBSTITUTED 5-AMINOPYRAZOLES AND USE THEREOF | CYP3A5, ABAT, TPMT | MAPK1 4445/4885ALDH1A1 260/4885ALOX15 577/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.